Latest From Alector Inc.
IPO market is expected to pick up in 2019 after a slow start, due in part to the government shutdown, and VC investment appears steady, but M&A outlook remains mixed.
Public Company Edition: Grossing $276m, Gossamer would have been the third-largest biopharma IPO in the US if it had launched last year. Also, recent public company financings include debt and follow-on offerings; and two more firms cut jobs – Capricor and Seres.
Gossamer took an infrequently used path to go public during a US government shutdown that's kept the SEC from processing new offerings. Also, IPO filings (and withdrawals) and follow-on offerings continued during the shutdown, while VC deals keep up a brisk pace.
Scrip spoke with Managing Director Julie Sunderland about Biomatics' new $300m fund. Also, Silicon Valley Bank reveals its surprising Leerink buy, Perceptive Advisors raises $675m, Roivant brings in another $200m, and cell and gene therapy financings surge in the third quarter.
Drug Discovery Tools
- Drug Discovery Tools
- Therapeutic Areas
- Neurology, Nervous System
- North America
- Parent & Subsidiaries
- Alector Inc.
- Senior Management
Arnon Rosenthal, PhD, Pres. & CEO
Robert Paul, MD, PhD, CMO
Robert King, PhD, Chief Dev. Officer
Sabah Oney, PhD, CBO
Calvin Yu, Head, Fin.
- Contact Info
Phone: (415) 231-5660
151 Oyster Point Blvd., Ste. 300
South San Francisco, CA 94080
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.